Aardvark Therapeutics' approach to obesity is to inhibit hunger (vs appetite). It has a key pivotal trial scheduled to read in Prader-Willi syndrome early next year, and is also working on weight loss episode artwork

EPISODE · Nov 11, 2025 · 8 MIN

Aardvark Therapeutics' approach to obesity is to inhibit hunger (vs appetite). It has a key pivotal trial scheduled to read in Prader-Willi syndrome early next year, and is also working on weight loss

from BiotechTV - News · host BiotechTV

Founder and CEO Tien Lee describes how Aardvark's approach focuses on the gut-brain axis.

Episode metadata supplied by the publisher feed · Published Nov 11, 2025

Embed this episode

Ready to play

Aardvark Therapeutics' approach to obesity is to inhibit hunger (vs appetite). It has a key pivotal trial scheduled to read in Prader-Willi syndrome early next year, and is also working on weight loss

0:00 8:46

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of BiotechTV - News?

This episode is 8 minutes long.

When was this BiotechTV - News episode published?

This episode was published on November 11, 2025.

Can I download this BiotechTV - News episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!